Dr Reddy’s Laboratories’ subsidiary, Aurigene Oncology Limited, received DCGI approval to conduct a phase-2 trial for India’s first novel autologous BCMA directed CAR-T cell therapy, Ribrecabtagene autoleucel, following promising phase-1 results showing significant clinical response in patients with relapsed or refractory multiple myeloma.
Related Posts
Union Budget 2025: What you need to know to DOGE the punches
- staff
- February 2, 2025
- 0
There are two types of capital gains: long-term and short-term. Indexation helps reduce taxable gains by adjusting for inflation. Long-term capital losses can only be […]
Sensex, Nifty gain in early trade amid global market rally and foreign fund inflows
The BSE Sensex increased by 241.68 points to reach 81,801.22, while the NSE Nifty gained 78.4 points to hit 25,014.80. Top performers included Power Grid […]
Bitcoin approaches $70,000 with speculators eyeing record highs
Bitcoin shows a bullish trend, targeting previous record levels with growing optimism in riskier assets amid upcoming US elections. Increased global liquidity and China’s economic […]